Literature DB >> 23506599

Effects of Naoxintong on atherosclerosis and inducible nitric oxide synthase expression in atherosclerotic rabbit.

Xiao-Nan Zhong1, Hong-Hao Wang, Zheng-Qi Lu, Yong-Qiang Dai, Jian-Hua Huang, Wei Qiu, Ya-Qing Shu, Wen Xu, Chen Cheng, Xue-Qiang Hu.   

Abstract

BACKGROUND: High levels of nitric oxide (NO) produced by inducible NO synthase (iNOS) have been associated with atherosclerosis processes. Naoxintong is a traditional Chinese medicine for treatment of cerebrovascular and cardiovascular disease. The aim of the present study was to detect and quantify changes of iNOS mRNA and NO levels in the vessel wall after the administration of Naoxintong in an atherosclerotic rabbit model.
METHODS: Forty New Zealand white rabbits were randomly divided into five groups (n = 8). Rabbits were fed a standard diet (group A), an atherogenic diet consisting of 79% standard feed + 1% cholesterol + 5% lard + 15% egg yolk powder (group B), an atherogenic diet with Naoxintong 0.25 mg×kg(-1)×d(-1) (group C), an atherogenic diet with Naoxintong 0.5 mg×kg(-1)×d(-1) (group D), or atherogenic diet with Naoxintong 1.0 mg×kg(-1)×d(-1) (group E) for 12 weeks.
RESULTS: Supplemented administration of Naoxintong led to a down-regulation of cholesterol (CHOL) (P < 0.001) and low-density lipoprotein (LDL) (P < 0.001). The trend became more notable as the dose of Naoxintong increased; group C vs. group B (CHOL, P = 0.568; LDL-cholesterol (LDL-C), P = 0.119), group D vs. group B (CHOL, P = 0.264; LDL-C, P = 0.027), group E vs. group B (CHOL, P = 0.028; LDL-C, P = 0.002). Atherosclerotic lesions in aorta were reduced in Naoxintong groups (groups C, D, E) compared to group B. Group B had higher iNOS mRNA (P = 0.001) and NO level (P < 0.001) than group A. Compared with the atherogenic diet fed-rabbits, Naoxintong supplements decreased the expression of iNOS mRNA (P < 0.001) and the NO level (P < 0.001) in the vessel wall. Groups given a higher Naoxintong dose exhibited greater benefits. iNOS mRNA and NO levels seemed to be reduced in group C, although the difference did not quite reach statistical significance (iNOS mRNA, P = 0.130; NO, P = 0.038). iNOS mRNA and NO levels significantly decreased in group D (iNOS mRNA, P = 0.019; NO, P = 0.018) and group E (iNOS mRNA, P = 0.004; NO, P < 0.001).
CONCLUSION: Naoxintong has beneficial effects on atherosclerosis treatment by reducing expression of iNOS mRNA and the NO level in the vessel wall.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23506599

Source DB:  PubMed          Journal:  Chin Med J (Engl)        ISSN: 0366-6999            Impact factor:   2.628


  9 in total

Review 1.  Salvia miltiorrhizaBurge (Danshen): a golden herbal medicine in cardiovascular therapeutics.

Authors:  Zhuo-Ming Li; Suo-Wen Xu; Pei-Qing Liu
Journal:  Acta Pharmacol Sin       Date:  2018-04-26       Impact factor: 6.150

2.  Pharmacokinetics of Caffeic Acid, Ferulic Acid, Formononetin, Cryptotanshinone, and Tanshinone IIA after Oral Administration of Naoxintong Capsule in Rat by HPLC-MS/MS.

Authors:  Jin Li; Yang Bai; Yun Bai; Ruichao Zhu; Wei Liu; Jun Cao; Mingrui An; Zhijing Tan; Yan-Xu Chang
Journal:  Evid Based Complement Alternat Med       Date:  2017-07-05       Impact factor: 2.629

3.  Naoxintong/PPARγ Signaling Inhibits Cardiac Hypertrophy via Activation of Autophagy.

Authors:  Shuping Yuan; Jianhua Jin; Lu Chen; Yongzhong Hou; Hong Wang
Journal:  Evid Based Complement Alternat Med       Date:  2017-02-15       Impact factor: 2.629

4.  Evaluation of the anti-inflammatory and antioxidant pharmcodynamic compoents of naoxintong capsules as a basis of broad spectrum effects.

Authors:  Bin Lv; Lina Deng; Tian Xie; Xing Wei; Xiao Liu; Wangxiao Tan; Xiaoying Wang; Xiumei Gao
Journal:  Pharm Biol       Date:  2021-12       Impact factor: 3.503

Review 5.  Atheroprotective Effects and Mechanisms of Postmarketing Chinese Patent Formulas in Atherosclerosis Models: A Systematic Review.

Authors:  Shiqi Chen; Xiaoxiao Wu; Tong Li; Yang Li; Baofu Wang; Weiting Cheng; Yu Teng; Jingjing Yang; Hui Meng; Lei Wang; Ziwen Lu; Yangyang Jiang; Yahong Wang; Mingjing Zhao
Journal:  Evid Based Complement Alternat Med       Date:  2021-11-27       Impact factor: 2.629

6.  Identification of "Multiple Components-Multiple Targets-Multiple Pathways" Associated with Naoxintong Capsule in the Treatment of Heart Diseases Using UPLC/Q-TOF-MS and Network Pharmacology.

Authors:  Xianghui Ma; Bin Lv; Pan Li; Xiaoqing Jiang; Qian Zhou; Xiaoying Wang; Xiumei Gao
Journal:  Evid Based Complement Alternat Med       Date:  2016-03-31       Impact factor: 2.629

7.  Naoxintong/PPARα Signaling Inhibits H9c2 Cell Apoptosis and Autophagy in Response to Oxidative Stress.

Authors:  Huimin Xu; Jianhua Jin; Lu Chen; Chunxiao Li; Qinggang Xu; Juanjuan Shi; Buchang Zhao; Yongzhong Hou; Hong Wang
Journal:  Evid Based Complement Alternat Med       Date:  2016-09-07       Impact factor: 2.629

8.  NaoXinTong Capsules inhibit the development of diabetic nephropathy in db/db mice.

Authors:  Shu Yang; Mengyang Liu; Yuanli Chen; Chuanrui Ma; Lipei Liu; Buchang Zhao; Yong Wang; Xiaoju Li; Yan Zhu; Xiumei Gao; Deling Kong; Yajun Duan; Jihong Han; Xiaoxiao Yang
Journal:  Sci Rep       Date:  2018-06-14       Impact factor: 4.379

9.  Protective effects of Naoxintong capsule alone and in combination with ticagrelor and atorvastatin in rats with Qi deficiency and blood stasis syndrome.

Authors:  Wei-Jian Zhang; Wei-Wei Su; Qing-Wei Lin; Yan He; Zeng-Hao Yan; Yong-Gang Wang; Pei-Bo Li; Hao Wu; Hong Liu; Hong-Liang Yao
Journal:  Pharm Biol       Date:  2020-12       Impact factor: 3.503

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.